A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells

Chimeric antigen receptor (CAR) T-cells are an emerging therapy for the treatment of relapsed/refractory B-cell malignancies. While CD19 CAR-T cells have been FDA-approved, CAR T-cells targeting CD22, as well as dual-targeting CD19/CD22 CAR T-cells, are currently being evaluated in clinical trials....

Descripción completa

Detalles Bibliográficos
Autores principales: Fergusson, Nathan J., Adeel, Komal, Kekre, Natasha, Atkins, Harold, Hay, Kevin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174241/
https://www.ncbi.nlm.nih.gov/pubmed/37180149
http://dx.doi.org/10.3389/fimmu.2023.1178403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174241/
https://www.ncbi.nlm.nih.gov/pubmed/37180149
http://dx.doi.org/10.3389/fimmu.2023.1178403

Ejemplares similares